A Pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy

Clinical Pharmacokinetics

Volumn 51, Issue 1, 2012, Pages 41-53

  Verstuyft, Céline ^a,b   Delavenne, Xavier ^c   Rousseau, Alexandra ^d   Robert, Annie ^d   Tod, Michel ^e   Diquet, Bertrand ^f   Lebot, Martine ^d   Jaillon, Patrice ^g   Becquemont, Laurent ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b EA4123   (France)

^c University Jean Monnet of Saint Etienne EA3065   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

Acenocoumarol; Anticoagulants; Coumarins; Cytochrome P450; Fluindione; Genetic polymorphism; Pharmacodynamic modelling; Pharmacogenetics; Pharmacokinetic modelling; Pharmacokinetic pharmacodynamic relationships; Pharmacokinetics; Pharmacology; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9; FLUINDIONE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1;

ADULT; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACENOCOUMAROL; ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BODY WEIGHT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; PHENINDIONE; POLYMORPHISM, GENETIC; SMOKING;

EID: 83455229580     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11595560-000000000-00000     Document Type: Article

References (52)

1. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002 Apr 3; 287 (13): 1690-8 (Pubitemid 34289221)
2. White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999 Nov; 107 (5): 414-24 (Pubitemid 29528329)
3. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40 (8): 587-603 (Pubitemid 32758581)
4. Visser LE, van Schaik RH, van Vliet M, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004 Jul; 92 (1): 61-6 (Pubitemid 39010868)
5. Pengo V, Pegoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006 Feb; 21 (1): 73-7 (Pubitemid 43231132)
6. Warot D, Berlin II, Aymard G, et al. Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. Fundam Clin Pharmacol 2000; 14 (3): 231-6 (Pubitemid 30413495)
7. BecquemontL. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol 2008 Oct; 64 (10): 953-60
8. Haining RL, Hunter AP, Veronese ME, et al. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996 Sep 15; 333 (2): 447-58 (Pubitemid 26304913)
9. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4 (1): 39-42 (Pubitemid 24106122)
10. Mark L, Marki-Zay J, Fodor L, et al. Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol. Orv Hetil 2005 Apr 17; 146 (16): 739-43 (Pubitemid 46034384)
11. Tassies D, Freire C, Pijoan J, et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002 Nov; 87 (11): 1185-91 (Pubitemid 35397778)
12. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006 Jul; 80 (1): 13-22 (Pubitemid 43964915)
13. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation.NEngl J Med 2008 Mar 6; 358 (10): 999-1008 (Pubitemid 351347099)
14. Li T, Chang CY, Jin DY, et al. Identification of the gene for vitaminKepoxide reductase. Nature 2004 Feb 5; 427 (6974): 541-4
15. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarintreated cohort supports genetic forecasting. Blood 2009 Jan 22; 113 (4): 784-92
16. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin. Blood 2005 Jan 15; 105 (2): 645-9 (Pubitemid 40070748)
17. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005 Jul 1; 106 (1): 135-40 (Pubitemid 40967184)
18. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 Jun 2; 352 (22): 2285-93 (Pubitemid 40740552)
19. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000 Oct 15; 109 (6): 481-8
20. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G〉A) and CYP2C9 genotypes. Clin Chem 2007 Jul; 53 (7): 1199-205 (Pubitemid 47020974)
21. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data.NEngl J Med 2009 Feb 19; 360 (8): 753-64
22. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005 Oct 1; 106 (7): 2329-33 (Pubitemid 41510803)
23. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008 Sep; 84 (3): 326-31
24. Cazaux V, Gauthier B, Elias A, et al. Predicting daily maintenance dose of fluindione, an oral anticoagulant drug. Thromb Haemost 1996 May; 75 (5): 731-3 (Pubitemid 26181541)
25. Mentré F, Pousset F, Comets E, et al. Population pharmacokineticpharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther 1998 Jan; 63 (1): 64-78 (Pubitemid 28070187)
26. Verstuyft C, Robert A,Morin S, et al. Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol 2003 Mar; 58 (11): 739-45 (Pubitemid 36399230)
27. Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993; 110 (1): 482-90 (Pubitemid 23257823)
28. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzymeinducing effect of cigarette smoking. Clin Pharmacol Ther 1991 Jan; 49 (1): 44-8
29. Simon T, Becquemont L, Hamon B, et al. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol 2001 Nov; 52 (5): 601-4
30. Geisen C, Luxembourg B, Watzka M, et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur J Clin Pharmacol 2010 Apr; 67 (4): 371-81
31. van Schie RM, Wessels JA, le Cessie S, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011 Aug; 32 (15): 1909-17
32. Morin S, Bodin L, Loriot MA, et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004 May; 75 (5): 403-14 (Pubitemid 38534561)
33. Larramendy-Gozalo C, Yang JQ, Verstuyft C, et al. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C〉T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol 2006 Jun; 98 (6): 611-3
34. Aymard G, Legrand M, Comets E, et al. Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998 Apr 10; 707 (1-2): 169-73 (Pubitemid 28198050)
35. Gill TS, Hopkins KJ, Rowland M. Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. Br J Clin Pharmacol 1988 May; 25 (5): 591-8
36. Thijssen HH, Drittij MJ, Vervoort LM, et al. Altered pharmacokinetics of R-and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther 2001 Sep; 70 (3): 292-8 (Pubitemid 32868494)
37. Reitsma PH, van der Heijden JF, Groot AP, et al.AC1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005 Oct; 2 (10): e312
38. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Anal 2005; 49: 1020-30
39. Minto C, Li B, Tattam B, et al. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation: intersubject variability in systemic absorption from the lung. Br J Clin Pharmacol 2000 Aug; 50 (2): 116-24 (Pubitemid 30612029)
40. Dayneka NL, Garg V, Jusko WJ. Comparison of four basicmodels of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993 Aug; 21 (4): 457-78 (Pubitemid 24025269)
41. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokineticpharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992 Oct; 20 (5): 511-28 (Pubitemid 23034413)
42. Brendel K, Comets E, Laffont C, et al. Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn 2010 Feb; 37 (1): 49-65
43. Louis TA. Finding the observed information matrix when using the EM algorithm. Journal of the Royal Statistical Society Series B (Methodological) 1982; 44 (2): 226-33
44. Holford N. The visual predictive check: superiority to standard diagnostic (Rorschach) plots [abstract]. 14th Population Approach Group in Europe; 2005 Jun 16-17; Pamplona [online]. Available from URL: http://www.pagemeeting. org/?abstract=738 [Accessed 2011 Nov 1]
45. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28 (11): 1284-90
46. Hamberg AK, Dahl ML, Barban M, et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007 Apr; 81 (4): 529-38 (Pubitemid 46452304)
47. Delavenne X, Laporte S, Demasles S, et al. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid. Fundam Clin Pharmacol 2009 Feb; 23 (1): 127-35
48. Comets E, Pousset F, Mentré F, et al. Prediction of fluindione maintenance dosage hampered by large intraindividual variability. Ther Drug Monit 2000 Dec; 22 (6): 668-75
49. Comets E, Mentré F, Pousset F, et al. Modeling INR data to predict maintenance fluindione dosage. Ther Drug Monit 1998 Dec; 20 (6): 631-9 (Pubitemid 28544292)
50. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44 (12): 1227-46 (Pubitemid 41832565)
51. Thijssen HH, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther 2003 Jul; 74 (1): 61-8 (Pubitemid 36776177)
52. Tillement JP, Thebault JJ, Mattei C, et al. Anticaogulant effect and plasma kinetics of fluorfluindione after a single dose in man. Eur J Clin Pharmacol 1975; 8: 271-5